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With the goal of identifying genes with a differential pattern of expression between invasive cervical carcinomas (CVX) and normal
cervical keratinocytes (NCK), we used oligonucleotide microarrays to interrogate the expression of 14,500 known genes in 11 primary
HPV16 and HPV18-infected stage IB–IIA cervical cancers and four primary normal cervical keratinocyte cultures. Hierarchical cluster
analysis of gene expression data identified 240 and 265 genes that exhibited greater than twofold up-regulation and down-regulation,
respectively, in primary CVX when compared to NCK. Cyclin-dependent kinase inhibitor 2A (CDKN2A/p16), mesoderm-specific
transcript, forkhead box M1, v-myb myeloblastosis viral oncogene homolog (avian)-like2 (v-Myb), minichromosome maintenance
proteins 2, 4, and 5, cyclin B1, prostaglandin E synthase (PTGES), topoisomerase II alpha (TOP2A), ubiquitin-conjugating enzyme
E2C, CD97 antigen, E2F transcription factor 1, and dUTP pyrophosphatase were among the most highly overexpressed genes in CVX
when compared to NCK. Down-regulated genes in CVX included transforming growth factor beta 1, transforming growth factor alpha,
CFLAR, serine proteinase inhibitors (SERPING1 and SERPINF1), cadherin 13, protease inhibitor 3, keratin 16, and tissue factor
pathway inhibitor-2 (TFPI-2). Differential expression of some of these genes including CDKN2A/p16, v-Myb, PTGES, and TOP2A was
validated by quantitative real-time PCR. Flow cytometry on primary CVX and NCK and immunohistochemical staining of formalin
fixed paraffin-embedded tumor specimens from which primary CVX cultures were derived as well as from a separate set of invasive
cervical cancers confirmed differential expression of the CDKN2A/p16 and PTGES markers on CVX versus NCK. These results
identify several genes that are coordinately disregulated in cervical cancer, likely representing common signaling pathways triggered by
HPV transformation. Moreover, these data obtained with highly purified primary tumor cultures highlight novel molecular features of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.09.045
Abbreviations: CVX, invasive cervical carcinomas; NCK, normal cervical keratinocytes.
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A.D. Santin et al. / Virology 331 (2005) 269–291270human cervical cancer and provide a foundation for the development of new type-specific diagnostic and therapeutic strategies for this
disease.
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Cervical cancer remains the second-most common cause
of cancer-related deaths in women worldwide, with about
450,000 new cases diagnosed each year (Bosch et al., 2002;
Jemal et al., 2003). Human papillomavirus (HPV) infection
represents the most important risk factor for the develop-
ment of cervical cancer (Bosch et al., 2002). Prevalence
surveys, large case-control studies, and case series have
unequivocally shown that HPV DNA can be detected in
cervical cancer specimens in 90–100% of cases, compared
with a prevalence of 5–20% in cervical specimens from
women identified as suitable epidemiological controls
(Bosch et al., 2002). Although more than 100 distinct
HPV genotypes have been described, and at least 20 are
associated with cervical cancer, HPV types 16 and 18 are
the most frequently detected in cervical cancer regardless of
the geographical origin of the patients (Bosch et al., 2002).
Although early stage cervical cancer can be cured by
radical surgery or radiotherapy with equal effectiveness
(Landoni et al., 1997), pelvic radiation represents the
standard therapy for the treatment of locally advanced
disease. Despite technological advances, however, up to
35% of patients overall will develop advanced, metastatic
disease, for which treatment results are poor. A deeper
understanding of the molecular basis of cervical cancer has
the potential to refine significantly the diagnosis and
management of these tumors and may eventually lead to
the development of novel, more specific and more effective
treatments for prevention of disease progression following
first-line therapy.
High-throughput comprehensive technologies for assay-
ing gene expression, such as high-density oligonucleotide
and cDNA microarrays, have recently been used in an
attempt to identify genes changes in keratinocytes associ-
ated with high-risk HPV infection and thus involved in
cervical carcinogenesis (Alazawi et al., 2002; Chang and
Laimins, 2000; Chen et al., 2003; Nees et al., 2001; Oh et
al., 2001). However, global gene expression studies related
to cervical cancer have so far been limited to investigations
of in vitro HPV-transfected human keratinocytes (Chang
and Laimins, 2000; Nees et al., 2001; Oh et al., 2001),
cervical low-grade squamous intraepithelial lesions (Ala-
zawi et al., 2002), or snap-frozen tumor biopsies (Chen et
al., 2003). In this study, we used oligonucleotide micro-
arrays containing more than 22,000 unique transcripts to
analyze the gene expression profiles of 15 primary cervical
cell lines [i.e., 11 primary HPV16- or HPV18-positivecervical cancer cultures (CVX) derived from early stage
disease and four normal cervical keratinocyte cell lines
(NCK)]. Short-term primary CVX and NCK cell cultures,
which minimize the risk of a selection bias inherent in any
long-term in vitro growth, provide an opportunity to study
differential gene expression between highly enriched and
homogeneous populations of tumors and normal cervical-
derived epithelial cells.
We report that mRNA fingerprints readily distinguish
CVX from NCK and identify a number of genes highly
differentially expressed between nontransformed keratino-
cytes and invasive cervical cancer. Some of the genes
identified are already known to be overexpressed in cervical
cancer and to play crucial roles during HPV carcinogenesis,
validating our criteria for determination of differentially
expressed genes, but many other variably expressed genes
represent novel findings. Quantitative RT-PCR was used to
validate differences in gene expression between CVX and
NCK for some of these genes, including cyclin-dependent
kinase inhibitor 2A (CDKN2A), v-myb myeloblastosis viral
oncogene homolog (avian)-like 2 (v-Myb), prostaglandin E
synthase (PTGES), and topoisomerase (TOP2A). The gene
expression product of CDKN2A (i.e., p16) was further
validated through flow cytometric analysis of primary
CVX and NCK and by immunohistochemical analysis of
formalin-fixed paraffin-embedded specimens from which
primary CVX cultures were derived as well as from a
separate and independent set of invasive cervical cancer
specimens.Results
Gene expression profiles distinguish CVX from NCK and
identify differentially expressed genes
Flash-frozen biopsies from cervical tumor tissue and
normal cervix may contain significant numbers of con-
taminant stromal cells as well as a variety of host-derived
immune cells (e.g., monocytes, dendritic cells, lympho-
cytes). In addition, because early stage cervical cancer
epithelial cells may represent a small proportion of the
total cells found in the cervix, it is often difficult to collect
primary material that is free of contaminating cells in
sufficient quantities to conduct comparative gene expres-
sion analyses. Short-term primary CVX and NCK cultures,
which minimize the risk of a selection bias inherent in any
long-term in vitro growth, may provide an opportunity to
Fig. 1. Hierarchical clustering of 505 genes with differential expression
between 11 CVX and 4 NCK groups (P b 0.01) using a twofold threshold.
The cluster is color coded using red for up-regulation, green for down-
regulation, and black for median expression. Agglomerative clustering of
genes is illustrated with dendrograms.
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populations of normal and tumor-derived epithelial cells.
Accordingly, comprehensive gene expression profiles of 11
primary CVX and four primary NCK cell lines were
generated using high-density oligonucleotide arrays with
22,215 probe sets, which in total interrogated some 14,500
genes. Out of the 22,215 probe sets, a total of 1354
showed both a greater than twofold change between
groups and detection = present calls in more than half of
the samples. The WRS test at level alpha = 0.05 revealed
that 982 of these expression changes were statistically
significant. Because the WRS test is a rank test, only seven
discrete WRS P values occur at or below alpha = 0.05. For
each P value, Table 1 shows the number of genes
discovered and 99% confidence maxima on the percentage
of discoveries that are false. At a WRS P value of 0.009,
the cumulative gene total was 505 with a 99% confidence
maximum of 20.48 false discoveries (4.05%). Of these 505
genes with WRS P b 0.01, 240 showed up-regulation and
265 showed down-regulation in CVX over NCK. The
cluster analysis performed on hybridization intensity
values for the 505 gene segments just described is
shown in Fig. 1. All four NCK were grouped together in
the leftmost columns. Similarly, in the rightmost columns
all 11 CVX were found to cluster together. The tight
clustering of CVX from NCK was bdrivenQ by two
distinct profiles of gene expression. The first was
represented by a group of 240 genes that were highly
expressed in CVX and underexpressed in NCK (Table 2).
Genes shown previously to be involved in cervical carci-
nogenesis are present on this list, providing some validity
to our array analysis, while others are novel in cervical
carcinogenesis. Included in this group of genes are cyclin-
dependent kinase inhibitor 2A (CDKN2A/p16), meso-
derm-specific transcript (MEST), forkhead box M1
(FOXM1), v-myb myeloblastosis viral oncogene homolog
(avian)-like 2, prostaglandin E synthase (PTGES), mini-
chromosome maintenance proteins (MCM) 2, 4, and 5,Table 1
False discoveries among differentially expressed genes
WRSa
P value
Numberb of genes
discovered
Percent false
discoveriesc (%)
0.0041 241 4.61
0.0061 361 4.18
0.0090 505 4.05
0.0131 632 4.38
0.0188 773 4.81
0.0265 876 5.68
0.0367 982 6.72
a Wilcoxon rank-sum test with normal approximation, applied to 1354
genes showing N2 change between groups and present calls N50% in the
higher expressing group.
b Number having WRS P value less than or equal to indicated value.
c 99%-Confidence Maximum on Number of False Discoveries expressed
as a percent of the Number of Genes Discovered, given that 1354 genes
were tested via WRS.cyclin B1, topoisomerase II alpha (TOP2A), ubiquitin-
conjugating enzyme E2C, CD97 antigen, E2F transcription
factor 1, catenin-beta, and dUTP pyrophosphatase (Table
2). The second profile was represented by 265 genes that
were highly expressed in NCK and underexpressed in
CVX (Table 3). Included in this group of genes are
differentiation-related genes and tumor suppressor genes
including transforming growth factor, beta 1, transforming
growth factor alpha, CFLAR, serine proteinase inhibitors
(SERPING1 and SERPINF1), cadherin 13, protease inhi-
bitor 3, and keratin 16.
Validation of the microarray data
We used q-RT-PCR assays to validate the microarray
data. Four highly differentially expressed genes between
CVX and NCK (i.e., CDKN2A, v-Myb, PTGES, and
TOP2A) were selected for q-RT-PCR analysis. A compar-
ison of the microarray and q-RT-PCR data for these genes is
shown in Fig. 2. Expression differences between CVX and
NCK for CDKN2A/p16 (P = 0.002), v-Myb (P = 0.03),
PTGES (P = 0.03), and TOP2A (P = 0.02) were readily
apparent (Table 2 and Fig. 2). Moreover, qRT-PCR data
were significantly correlated to microarray data for the
above four genes, as determined by Spearman rank
correlation as follows: CDKN2A/p16 (s = 0.5393, P =
0.0380); v-Myb (s = 0.8101, P = 0.0003); PTGES (s =
0.8136, P = 0.0002); and TOP2A (s = 0.6357, P =
Table 2
Up-regulated genes expressed at least twofold higher in CVX compared with NCK
U133A
probe set
Gene
symbol
WRS
P value
Average
for CVX
Ratio
CVX/NCK
Activity or Description
205081_at CRIP1 0.004075 1662.5 105.39 cysteine-rich protein 1 (intestinal)
207069_s_at MADH6 0.009023 221.5 18.62 MAD, mothers against decapentaplegic homolog 6
(Drosophila)
221436_s_at GRCC8 0.004075 1150.3 11.46 likely ortholog of mouse gene-rich cluster, C8 gene
208510_s_at PPARG 0.006112 365.4 10.54 peroxisome proliferative activated receptor, gamma
209644_x_at CDKN2A 0.004075 7829.7 10.05 cyclin-dependent kinase inhibitor 2A (melanoma, p16,
inhibits CDK4)
204560_at FKBP5 0.004075 525.3 9.50 FK506 binding protein 5
206858_s_at HOXC6 0.009023 498.4 9.11 homeobox C6
207039_at CDKN2A 0.004075 2616.4 9.05 cyclin-dependent kinase inhibitor 2A (melanoma, p16,
inhibits CDK4)
202016_at MEST 0.004075 2220.9 7.99 mesoderm-specific transcript homolog (mouse)
218959_at HOXC10 0.009023 850.3 7.46 homeobox C10
202580_x_at FOXM1 0.004075 1624.4 7.42 forkhead box M1
201710_at MYBL2 0.004075 1458.0 6.71 v-myb myeloblastosis viral oncogene homolog
(avian)-like 2
203276_at LMNB1 0.006112 496.7 6.59 lamin B1
204766_s_at NUDT1 0.006112 442.3 6.58 nudix (nucleoside diphosphate linked moiety X)-type
motif 1
204641_at NEK2 0.004075 667.3 6.42 NIMA (never in mitosis gene a)-related kinase 2
201291_s_at TOP2A 0.009023 505.9 6.38 topoisomerase (DNA) II alpha 170 kDa
216212_s_at DKC1 0.009023 978.5 6.31 dyskeratosis congenita 1, dyskerin
201970_s_at NASP 0.009023 1358.5 6.14 nuclear autoantigenic sperm protein (histone-binding)
219978_s_at ANKT 0.004075 990.0 6.08 nucleolar protein ANKT
207388_s_at PTGES 0.004075 2539.5 5.99 prostaglandin E synthase
213008_at FLJ10719 0.006112 429.0 5.89 hypothetical protein FLJ10719
205862_at GREB1 0.006112 54.8 5.75 GREB1 protein
212141_at MCM4 0.004075 1137.1 5.59 MCM4 minichromosome maintenance deficient 4
(S. cerevisiae)
201774_s_at CNAP1 0.004075 1672.0 5.54 chromosome condensation-related SMC-associated
protein 1
218039_at ANKT 0.006112 2027.1 5.54 nucleolar protein ANKT
210052_s_at C20orf1 0.004075 2786.1 5.51 chromosome 20 open reading frame 1
202954_at UBE2C 0.006112 4354.1 5.23 ubiquitin-conjugating enzyme E2C
210367_s_at PTGES 0.004075 3098.6 5.20 prostaglandin E synthase
202910_s_at CD97 0.004075 495.6 5.02 topoisomerase (DNA) II alpha
208079_s_at STK6 0.004075 1915.1 4.93 serine/threonine kinase 6
203418_at CCNA2 0.009023 1013.0 4.85 cyclin A2
209714_s_at CDKN3 0.004075 1327.1 4.84 cyclin-dependent kinase inhibitor 3 (CDK2-associated
dual specificity phosphatase)
218755_at RAB6KIFL 0.006112 1015.1 4.83 RAB6 interacting, kinesin-like (rabkinesin6)
218009_s_at PRC1 0.006112 2515.3 4.81 protein regulator of cytokinesis 1
204317_at – 0.004075 163.0 4.80 unknown (protein for MGC:15422) (Homo sapiens),
mRNA sequence
218741_at MGC861 0.004075 889.6 4.71 hypothetical protein MGC861
202705_at CCNB2 0.004075 2283.1 4.61 cyclin B2
219555_s_at BM039 0.006112 798.7 4.59 uncharacterized bone marrow protein BM039
204233_s_at CHK 0.004075 480.9 4.59 choline kinase
202251_at HPRP3P 0.004075 493.1 4.55 U4/U6-associated RNA splicing factor
202107_s_at MCM2 0.006112 5267.9 4.55 MCM2 minichromosome maintenance deficient 2,
mitotin (S. cerevisiae)
213599_at OIP5 0.004075 887.8 4.53 Opa-interacting protein 5
201755_at MCM5 0.009023 1058.4 4.53 MCM5 minichromosome maintenance deficient 5,
cell division cycle 46 (S. cerevisiae)
221206_at - 0.009023 373.4 4.50
212552_at HPCAL1 0.004075 4490.3 4.49 hippocalcin-like 1
204827_s_at CCNF 0.004075 263.1 4.48 cyclin F
222039_at (EST) 0.006112 1031.2 4.37 ESTs, moderately similar to PRO0478 protein
(H. sapiens)
202870_s_at CDC20 0.004075 3250.6 4.36 CDC20 cell division cycle 20 homolog (S. cerevisiae)
205462_s_at HPCAL1 0.004075 1501.7 4.35 hippocalcin-like 1
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U133A
probe set
Gene
symbol
WRS
P value
Average
for CVX
Ratio
CVX/NCK
Activity or Description
203967_at CDC6 0.009023 1133.1 4.22 CDC6 cell division cycle 6 homolog (S. cerevisiae)
214710_s_at CCNB1 0.006112 2481.4 4.21 cyclin B1
202589_at TYMS 0.009023 5175.0 4.17 thymidylate synthetase
204023_at RFC4 0.004075 2093.9 4.14 replication factor C (activator 1) 4, 37 kDa
204092_s_at STK6 0.006112 1858.6 4.13 serine/threonine kinase 6
208072_s_at DGKD 0.004075 552.5 4.10 diacylglycerol kinase, delta 130 kDa
201663_s_at SMC4L1 0.009023 669.9 4.06 SMC4 structural maintenance of chromosomes
4-like 1 (yeast)
204947_at E2F1 0.006112 517.9 4.05 E2F transcription factor 1
204962_s_at CENPA 0.004075 741.6 4.02 centromere protein A, 17 kDa
202976_s_at RHOBTB3 0.009023 442.0 4.00 Rho-related BTB domain containing 3
219143_s_at FLJ20374 0.009023 997.9 3.95 hypothetical protein FLJ20374
204709_s_at KNSL5 0.009023 134.2 3.91 kinesin-like 5 (mitotic kinesin-like protein 1)
202095_s_at BIRC5 0.006112 1538.6 3.90 baculoviral IAP repeat-containing 5 (survivin)
212282_at MAC30 0.004075 1940.1 3.84 hypothetical protein MAC30
210004_at OLR1 0.009023 217.5 3.84 oxidized low-density lipoprotein (lectin-like)
receptor 1
213610_s_at – 0.009023 123.3 3.84 unknown (protein for IMAGE:3354344)
(H. sapiens), mRNA sequence
208161_s_at ABCC3 0.006112 608.0 3.77 ATP binding cassette, subfamily C (CFTR/MRP),
member 3
209406_at BAG2 0.004075 583.6 3.76 BCL2-associated athanogene 2
216237_s_at MCM5 0.009023 2762.4 3.68 MCM5 minichromosome maintenance deficient 5,
cell division cycle 46 (S. cerevisiae)
209172_s_at CENPF 0.004075 149.8 3.68 centromere protein F, 350/400 kDa (mitosin)
210206_s_at DDX11 0.006112 352.0 3.66 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11
(CHL1-like helicase homolog, S. cerevisiae)
202240_at PLK 0.004075 980.0 3.64 polo-like kinase (Drosophila)
202094_at BIRC5 0.009023 577.0 3.63 baculoviral IAP repeat-containing 5 (survivin)
203046_s_at TIMELESS 0.004075 823.7 3.63 timeless homolog (Drosophila)
212621_at KIAA0286 0.009023 578.0 3.61 KIAA0286 protein
208103_s_at LANPL 0.009023 507.6 3.60 leucine-rich acidic nuclear protein-like
203432_at (EST) 0.006112 1461.0 3.58 ESTs
219512_at C20orf172 0.009023 215.8 3.56 chromosome 20 open reading frame 172
204026_s_at ZWINT 0.006112 2673.5 3.54 ZW10 interactor
221591_s_at FLJ10156 0.009023 757.7 3.49 hypothetical protein FLJ10156
203968_s_at CDC6 0.006112 941.6 3.48 CDC6 cell division cycle 6 homolog (S. cerevisiae)
202779_s_at E2-EPF 0.004075 8293.5 3.45 ubiquitin carrier protein
204033_at TRIP13 0.006112 1741.5 3.44 thyroid hormone receptor interactor 13
203832_at SNRPF 0.006112 3153.1 3.43 small nuclear ribonucleoprotein polypeptide F
217821_s_at WBP11 0.004075 1204.5 3.43 WW domain binding protein 11
211450_s_at MSH6 0.006112 891.7 3.43 mutS homolog 6 (Escherichia coli)
216669_at (FLJ20286) 0.006112 63.2 3.42 H. sapiens cDNA FLJ20286 fis, clone HEP04358,
mRNA sequence
204822_at TTK 0.006112 474.0 3.41 TTK protein kinase
219502_at FLJ10858 0.004075 392.4 3.37 hypothetical protein FLJ10858
203145_at SPAG5 0.006112 762.0 3.36 sperm-associated antigen 5
219588_s_at FLJ20311 0.006112 802.2 3.34 hypothetical protein FLJ20311
203625_x_at (FLJ22571) 0.009023 1085.2 3.34 H. sapiens cDNA: FLJ22571 fis, clone HSI02239,
mRNA sequence
205167_s_at CDC25C 0.004075 366.2 3.32 cell division cycle 25C
204147_s_at TFDP1 0.004075 667.9 3.31 transcription factor Dp-1
213906_at MYBL1 0.006112 161.6 3.31 v-myb myeloblastosis viral oncogene homolog
(avian)-like 1
215116_s_at DNM1 0.006112 693.9 3.28 dynamin 1
212281_s_at MAC30 0.004075 1879.4 3.22 hypothetical protein MAC30
201897_s_at CKS1B 0.006112 4568.0 3.21 CDC28 protein kinase regulatory subunit 1B
221648_s_at (FLJ21998) 0.004075 399.9 3.19 H. sapiens cDNA: FLJ21998 fis, clone HEP06592,
highly similar to AF151904 H. sapiens CGI-146
protein mRNA, mRNA sequence
208955_at DUT 0.004075 810.9 3.18 dUTP pyrophosphatase
211519_s_at KNSL6 0.004075 944.3 3.18 kinesin-like 6 (mitotic centromere-associated kinesin)
(continued on next page)
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219258_at FLJ20516 0.009023 511.3 3.18 hypothetical protein FLJ20516
212525_s_at H2AFX 0.004075 405.9 3.15 H2A histone family, member X
1053_at RFC2 0.009023 1062.0 3.13 replication factor C (activator 1) 2, 40 kDa
204689_at HHEX 0.004075 182.8 3.07 hematopoietically expressed homeobox
202503_s_at KIAA0101 0.004075 4870.9 3.07 KIAA0101 gene product
218979_at FLJ12888 0.009023 495.9 3.07 hypothetical protein FLJ12888
204318_s_at GTSE1 0.009023 536.4 3.06 G-2 and S-phase expressed 1
221677_s_at DONSON 0.009023 605.2 3.06 downstream neighbor of SON
205356_at USP13 0.004075 654.9 3.05 ubiquitin-specific protease 13 (isopeptidase T-3)
208694_at PRKDC 0.006112 928.1 3.04 protein kinase, DNA-activated, catalytic polypeptide
206511_s_at SIX2 0.009023 211.3 2.99 sine oculis homeobox homolog 2 (Drosophila)
205053_at PRIM1 0.009023 1168.5 2.98 primase, polypeptide 1, 49 kDa
209053_s_at WHSC1 0.009023 864.3 2.96 Wolf–Hirschhorn syndrome candidate 1
212279_at MAC30 0.006112 2371.8 2.95 hypothetical protein MAC30
209408_at KNSL6 0.004075 1835.2 2.94 kinesin-like 6 (mitotic centromere-associated kinesin)
203637_s_at MID1 0.006112 441.3 2.93 midline 1 (Opitz/BBB syndrome)
205296_at – 0.004075 74.2 2.92
205519_at FLJ12973 0.009023 280.3 2.91 hypothetical protein FLJ12973
214507_s_at RRP4 0.006112 822.1 2.91 homolog of yeast RRP4 (ribosomal RNA processing 4),
3V-5V-exoribonuclease
204826_at CCNF 0.004075 520.9 2.90 cyclin F
208447_s_at PRPS1 0.006112 1244.9 2.88 phosphoribosyl pyrophosphate synthetase 1
202942_at ETFB 0.004075 2047.6 2.84 electron-transfer-flavoprotein, beta polypeptide
212655_at BDG-29 0.004075 312.9 2.83 BDG-29 protein
211717_at MGC15396 0.004075 592.3 2.83 hypothetical protein MGC15396
209527_at RRP4 0.006112 573.3 2.82 homolog of yeast RRP4 (ribosomal RNA processing 4),
3V-5V-exoribonuclease
222250_s_at DKFZP434B168 0.004075 295.1 2.79 DKFZP434B168 protein
212349_at POFUT1 0.004075 335.6 2.79 protein O-fucosyltransferase 1
218365_s_at FLJ10514 0.009023 646.6 2.79 hypothetical protein FLJ10514
219061_s_at DXS9879E 0.009023 1531.8 2.77 DNA segment on chromosome X (unique) 9879
expressed sequence
212379_at GART 0.006112 1102.3 2.77 phosphoribosylglycineamide formyltransferase,
phosphoribosylglycineamide synthetase,
phosphoribosylaminoimidazole synthetase
211713_x_at KIAA0101 0.009023 446.5 2.77 KIAA0101 gene product
203554_x_at PTTG1 0.009023 6061.0 2.76 pituitary tumor-transforming 1
210216_x_at RAD1 0.004075 1256.7 2.76 RAD1 homolog (S. pombe)
201043_s_at ANP32A 0.006112 864.4 2.74 acidic (leucine-rich) nuclear phosphoprotein 32 family,
member A
209832_s_at CDT1 0.009023 558.2 2.72 DNA replication factor
209507_at RPA3 0.004075 3086.1 2.71 replication protein A3, 14 kDa
222270_at KIAA1387 0.004075 76.2 2.71 KIAA1387 protein
203660_s_at PCNT2 0.004075 416.2 2.70 pericentrin 2 (kendrin)
200884_at CKB 0.006112 1345.4 2.70 creatine kinase, brain
202309_at MTHFD1 0.004075 2550.5 2.70 methylenetetrahydrofolate dehydrogenase
(NADP + dependent), methylenetetrahydrofolate
cyclohydrolase, formyltetrahydrofolate synthetase
208445_s_at BAZ1B 0.009023 691.0 2.70 bromodomain adjacent to zinc finger domain, 1B
202602_s_at HTATSF1 0.004075 643.1 2.69 HIV TAT-specific factor 1
202911_at MSH6 0.009023 1609.6 2.69 mutS homolog 6 (E. coli)
39966_at CSPG5 0.006112 178.1 2.69 chondroitin sulfate proteoglycan 5 (neuroglycan C)
210115_at RPL39L 0.004075 1148.9 2.67 ribosomal protein L39-like
214035_x_at NPIP 0.006112 1322.6 2.66 nuclear pore complex-interacting protein
205425_at HIP1 0.009023 237.8 2.66 huntingtin-interacting protein 1
211080_s_at NEK2 0.009023 302.3 2.65 NIMA (never in mitosis gene a)-related kinase 2
220011_at MGC2603 0.009023 620.5 2.65 hypothetical protein MGC2603
2028_s_at E2F1 0.009023 547.2 2.65 E2F transcription factor 1
216969_s_at KNSL4 0.004075 413.3 2.64 kinesin-like 4
201697_s_at DNMT1 0.009023 1883.1 2.64 DNA (cytosine-5-)-methyltransferase 1
204460_s_at RAD1 0.004075 858.8 2.62 RAD1 homolog (S. pombe)
212483_at IDN3 0.006112 216.4 2.61 IDN3 protein
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214086_s_at ADPRTL2 0.004075 626.6 2.59 ADP-ribosyltransferase (NAD+; poly(ADP-ribose)
polymerase)-like 2
221311_x_at DJ122O8.2 0.004075 300.2 2.58 hypothetical protein dJ122O8.2
211042_x_at – 0.004075 993.6 2.55 similar to melanoma adhesion molecule (H. sapiens),
mRNA sequence
209440_at PRPS1 0.009023 1836.9 2.54 phosphoribosyl pyrophosphate synthetase 1
200875_s_at NOL5A 0.009023 2193.3 2.53 nucleolar protein 5A (56 kDa with KKE/D repeat)
216299_s_at XRCC3 0.009023 185.8 2.52 X-ray repair complementing defective repair in Chinese
hamster cells 3
221952_x_at KIAA1393 0.004075 7245.2 2.51 KIAA1393 protein
213378_s_at DDX11 0.004075 979.4 2.51 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11
(CHL1-like helicase homolog, S. cerevisiae)
203825_at BRD3 0.004075 1424.2 2.50 bromodomain containing 3
222147_s_at FLJ12785 0.004075 466.8 2.49 hypothetical protein FLJ12785
219004_s_at C21orf45 0.009023 503.5 2.49 chromosome 21 open reading frame 45
201589_at SMC1L1 0.009023 1778.6 2.49 SMC1 structural maintenance of chromosomes
1-like 1 (yeast)
206499_s_at CHC1 0.006112 1665.1 2.47 chromosome condensation 1
218904_s_at FLJ10110 0.004075 232.1 2.47 hypothetical protein FLJ10110
206261_at ZNF239 0.009023 247.7 2.44 zinc finger protein 239
203564_at FANCG 0.009023 1117.1 2.44 Fanconi anemia, complementation group G
202487_s_at H2AV 0.004075 4737.6 2.43 histone H2A.F/Z variant
215708_s_at PRIM2A 0.006112 368.5 2.42 primase, polypeptide 2A, 58 kDa
209932_s_at DUT 0.009023 3621.3 2.42 dUTP pyrophosphatase
215722_s_at SNRPA1 0.004075 579.1 2.41 small nuclear ribonucleoprotein polypeptide AV
204461_x_at RAD1 0.006112 881.1 2.41 RAD1 homolog (S. pombe)
203022_at RNASEH2A 0.009023 2305.8 2.41 ribonuclease H2, large subunit
204849_at TCFL5 0.009023 889.5 2.40 transcription factor-like 5 (basic helix-loop-helix)
209520_s_at NCBP1 0.009023 412.8 2.40 nuclear cap binding protein subunit 1, 80 kDa
37425_g_at C6orf18 0.006112 326.1 2.40 chromosome 6 open reading frame 18
205339_at SIL 0.009023 415.0 2.39 TAL1 (SCL) interrupting locus
221550_at COX15 0.004075 207.8 2.38 COX15 homolog, cytochrome c oxidase assembly
protein (yeast)
221556_at CDC14B 0.009023 358.7 2.38 CDC14 cell division cycle 14 homolog B (S. cerevisiae)
203588_s_at TFDP2 0.009023 795.2 2.38 transcription factor Dp-2 (E2F dimerization partner 2)
208985_s_at EIF3S1 0.004075 1203.8 2.37 eukaryotic translation initiation factor 3, subunit 1 alpha
35 kDa
210544_s_at ALDH3A2 0.004075 791.2 2.36 aldehyde dehydrogenase 3 family, member A2
212330_at TFDP1 0.006112 2623.8 2.35 transcription factor Dp-1
205176_s_at ITGB3BP 0.006112 888.8 2.34 integrin beta 3 binding protein (beta3-endonexin)
208511_at PTTG3 0.009023 310.4 2.32 pituitary tumor-transforming 3
203062_s_at KIAA0170 0.004075 733.1 2.32 KIAA0170 gene product
204449_at PDCL 0.009023 93.3 2.32 phosducin-like
217822_at WBP11 0.009023 1584.7 2.32 WW domain binding protein 11
200956_s_at SSRP1 0.004075 2249.4 2.32 structure-specific recognition protein 1
218440_at MCCC1 0.006112 559.6 2.31 methylcrotonoyl-coenzyme A carboxylase 1 (alpha)
221931_s_at SEC13L 0.009023 1053.9 2.30 sec13-like protein
204649_at TROAP 0.004075 544.0 2.28 trophinin-associated protein (tastin)
215933_s_at HHEX 0.009023 160.6 2.28 hematopoietically expressed homeobox
208939_at SPS 0.006112 676.6 2.27 selenophosphate synthetase
212901_s_at CSTF2T 0.009023 313.5 2.27 likely ortholog of mouse variant polyadenylation
protein CSTF-64
213090_s_at TAF4 0.004075 670.9 2.27 TAF4 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 135 kDa
211040_x_at GTSE1 0.004075 905.1 2.26 G-2 and S-phase expressed 1
209161_at PRPF4 0.006112 2008.7 2.25 PRP4 pre-mRNA processing factor 4 homolog (yeast)
210625_s_at AKAP1 0.006112 523.1 2.24 A kinase (PRKA) anchor protein 1
218269_at RNASE3L 0.004075 1094.8 2.24 putative ribonuclease III
211318_s_at RAE1 0.006112 2066.9 2.23 RAE1 RNA export 1 homolog (S. pombe)
212381_at USP24 0.009023 195.1 2.22 ubiquitin-specific protease 24
208644_at ADPRT 0.009023 1558.0 2.22 ADP-ribosyltransferase [NAD+; poly(ADP-ribose)
polymerase]
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209273_s_at MGC4276 0.004075 824.0 2.21 hypothetical protein MGC4276 similar to CG8198
219531_at FLJ10565 0.006112 486.4 2.21 hypothetical protein FLJ10565
209450_at OSGEP 0.004075 438.0 2.20 O-sialoglycoprotein endopeptidase
202053_s_at ALDH3A2 0.009023 2100.1 2.20 aldehyde dehydrogenase 3 family, member A2
212801_at CIT 0.004075 860.0 2.20 citron (rho-interacting, serine/threonine kinase 21)
206055_s_at SNRPA1 0.009023 1212.0 2.20 small nuclear ribonucleoprotein polypeptide AV
218653_at SLC25A15 0.009023 662.0 2.19 solute carrier family 25 (mitochondrial carrier;
ornithine transporter) member 15
207746_at POLQ 0.006112 206.3 2.18 polymerase (DNA directed), theta
202726_at LIG1 0.006112 577.9 2.18 ligase I, DNA, ATP-dependent
212287_at JJAZ1 0.009023 836.4 2.17 joined to JAZF1
220773_s_at GPHN 0.004075 361.1 2.17 gephyrin
218947_s_at FLJ10486 0.006112 454.1 2.13 hypothetical protein FLJ10486
219875_s_at PNAS-4 0.009023 111.1 2.12 CGI-146 protein
202622_s_at SCA2 0.006112 507.3 2.12 spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2,
autosomal dominant, ataxin 2)
209162_s_at PRPF4 0.004075 1404.4 2.12 PRP4 pre-mRNA processing factor 4 homolog (yeast)
218176_at MAGEF1 0.009023 695.9 2.11 MAGEF1 protein
220094_s_at FLJ20958 0.009023 1742.0 2.10 hypothetical protein FLJ20958
218229_s_at POGK 0.006112 1467.9 2.09 pogo transposable element with KRAB domain
200975_at PPT1 0.004075 2750.4 2.08 palmitoyl-protein thioesterase 1 (ceroid-lipofuscinosis,
neuronal 1, infantile)
203721_s_at CGI-48 0.009023 1447.4 2.08 CGI-48 protein
212170_at RBM12 0.006112 168.9 2.06 RNA binding motif protein 12
221058_s_at CKLF1 0.009023 732.4 2.06 chemokine-like factor 1
219161_s_at CKLF1 0.004075 1185.7 2.06 chemokine-like factor 1
208956_x_at DUT 0.004075 4399.2 2.04 dUTP pyrophosphatase
209433_s_at PPAT 0.009023 361.7 2.04 phosphoribosyl pyrophosphate amidotransferase
201528_at RPA1 0.009023 1958.2 2.03 replication protein A1, 70 kDa
201675_at AKAP1 0.009023 1451.6 2.03 A kinase (PRKA) anchor protein 1
202466_at POLS 0.006112 1679.5 2.02 polymerase (DNA directed) Sigma
203338_at PPP2R5E 0.009023 719.0 2.02 protein phosphatase 2, regulatory subunit B (B56),
epsilon isoform
201764_at MGC5576 0.006112 2131.4 2.01 hypothetical protein MGC5576
204228_at PPIH 0.004075 1605.2 2.01 peptidyl prolyl isomerase H (cyclophilin H)
219644_at NY-REN-58 0.004075 96.8 2.01 NY-REN-58 antigen
218770_s_at FLJ10315 0.004075 778.2 2.01 hypothetical protein FLJ10315
218586_at C20orf20 0.004075 1017.5 2.01 chromosome 20 open reading frame 20
A.D. Santin et al. / Virology 331 (2005) 269–2912760.0109). Thus, q-RT-PCR data suggest that most array
probe sets are likely to measure accurately the levels of
the intended transcript within a complex mixture of
transcripts.
CDKN2A/p16 expression by flow cytometry on primary
CVX and NCK cell lines
An important issue is whether differences in gene
expression result in meaningful differences in protein
expression. Because the CDKN2A gene product, the p16
protein, has recently been explored as a potential diagnostic
marker for cervical squamous and glandular neoplastic
lesions as well as to identify individual dyskaryotic cells in
Pap smears (Murphy et al., 2003), expression of p16 protein
by flow cytometry was analyzed on all the 15 primary cell
lines. As a positive control, the HPV18-positive HeLa
cervical cancer cell line, which is known to overexpress
p16, was also studied. As representatively shown in Fig. 3,high intracellular levels of p16 expression was found on all
primary CVX cell lines tested (100% positive cells for all
CVX), with mean fluorescence intensity (MFI) ranging
from 116 to 280. As expected, HeLa cells expressed high
levels of p16 by flow cytometry (data not shown). In
contrast, primary NCK cell lines were all found negative for
p16 expression (P b 0.01) (Fig. 3). These results show that
high expression of the p16 gene product at the RNA level
by the CVX cell lines correlates tightly with high protein
expression.
CDKN2A/p16 and PTGES expression by immunohistology
on CVX and NCK tissue blocks
To determine whether the high expression of the
CDKN2A/p16 and PTGES genes detected by microarray
and confirmed by q-RT-PCR in primary cervical cancer
cell lines is the result of a selection of a subpopulation of
cancer cells present in the original tumor, or whether in
Table 3
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208539_x_at SPRR2B 0.004075 8837.1 101.37 small proline-rich protein 2B
219554_at RHCG 0.004075 2320.8 51.52 Rhesus blood group, C glycoprotein
205680_at MMP10 0.004075 3399.3 48.22 matrix metalloproteinase 10 (stromelysin 2)
213796_at (SPRK) 0.004075 5268.4 31.10 Small proline-rich protein SPRK (human,
odontogenic keratocysts, mRNA partial, 317 nt),
mRNA sequence
202917_s_at S100A8 0.004075 10,169.9 27.80 S100 calcium binding protein A8 (calgranulin A)
220620_at NICE-1 0.004075 2336.7 25.95 NICE-1 protein
214370_at S100A8 0.004075 229.3 23.20 S100 calcium binding protein A8 (calgranulin A)
218312_s_at FLJ12895 0.004075 613.6 21.94 hypothetical protein FLJ12895
206371_at FOLR3 0.004075 1295.4 20.95 folate receptor 3 (gamma)
203562_at FEZ1 0.004075 5812.2 19.39 fasciculation and elongation protein zeta 1 (zygin I)
204818_at HSD17B2 0.006112 2237.0 18.86 hydroxysteroid (17-beta) dehydrogenase 2
221898_at T1A-2 0.004075 565.1 18.80 lung type-I cell membrane-associated glycoprotein
205064_at SPRR1B 0.004075 12,148.4 18.48 small proline-rich protein 1B (cornifin)
204475_at MMP1 0.004075 7151.8 18.31 matrix metalloproteinase 1 (interstitial collagenase)
203691_at PI3 0.004075 9690.8 18.26 protease inhibitor 3, skin-derived (SKALP)
220724_at FLJ21511 0.004075 192.3 17.82 hypothetical protein FLJ21511
219630_at DD96 0.004075 1999.5 16.94 epithelial protein up-regulated in carcinoma,
membrane-associated protein 17
204463_s_at EDNRA 0.004075 205.8 15.77 endothelin receptor type A
210065_s_at UPK1B 0.004075 856.7 15.52 uroplakin 1B
209570_s_at D4S234E 0.004075 264.4 14.90 DNA segment on chromosome 4 (unique)
234 expressed sequence
207526_s_at IL1RL1 0.004075 1694.8 14.26 interleukin 1 receptor-like 1
214549_x_at SPRR1A 0.004075 4380.8 13.57 small proline-rich protein 1A
202828_s_at MMP14 0.004075 1264.2 12.81 matrix metalloproteinase 14 (membrane-inserted)
214702_at FN1 0.004075 405.6 12.43 fibronectin 1
204470_at CXCL1 0.006112 1774.5 12.13 chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity, alpha)
211597_s_at LAGY 0.004075 1096.1 11.78 homeodomain only protein
212657_s_at IL1RN 0.004075 5546.0 11.66 interleukin 1 receptor antagonist
209278_s_at TFPI2 0.009023 7097.0 11.53 tissue factor pathway inhibitor 2
220322_at IL1F9 0.004075 713.0 11.06 interleukin 1 family, member 9
218990_s_at SPRR3 0.004075 2080.6 10.99 small proline-rich protein 3
217109_at MUC4 0.009023 293.6 10.97 mucin 4, tracheobronchial
219655_at C7orf10 0.004075 1192.4 10.74 chromosome 7 open reading frame 10
209800_at KRT16 0.009023 9227.6 10.58 keratin 16 (focal nonepidermolytic palmoplantar
keratoderma)
205899_at CCNA1 0.009023 1237.4 9.61 cyclin A1
219993_at SOX17 0.004075 786.6 9.56 SRY (sex determining region Y)-box 17
41469_at (PI3?) 0.004075 7523.9 9.40
205479_s_at PLAU 0.004075 8178.8 9.35 plasminogen activator, urokinase
213680_at KRT6B 0.006112 9562.0 9.03 keratin 6B
201667_at GJA1 0.006112 1507.4 8.97 gap junction protein, alpha 1, 43 kDa (connexin 43)
204464_s_at EDNRA 0.004075 690.9 8.81 endothelin receptor type A
205778_at KLK7 0.004075 3534.8 8.79 kallikrein 7 (chymotryptic, stratum corneum)
211756_at PTHLH 0.009023 2389.2 8.78 parathyroid hormone-like hormone
211668_s_at PLAU 0.004075 8066.0 8.51 plasminogen activator, urokinase
222020_s_at HNT 0.004075 231.3 8.37 neurotrimin
216243_s_at IL1RN 0.006112 3602.1 8.29 interleukin 1 receptor antagonist
202859_x_at IL8 0.006112 3803.8 8.18 interleukin 8
212659_s_at IL1RN 0.004075 2445.9 8.16 interleukin 1 receptor antagonist
209949_at NCF2 0.004075 1197.1 8.15 neutrophil cytosolic factor 2 (65 kDa, chronic
granulomatous disease, autosomal 2)
209569_x_at D4S234E 0.004075 1014.5 7.99 DNA segment on chromosome 4 (unique)
234 expressed sequence
210355_at PTHLH 0.004075 1802.2 7.69 parathyroid hormone-like hormone
214701_s_at FN1 0.004075 4124.9 7.69 fibronectin 1
207850_at CXCL3 0.009023 640.5 7.66 chemokine (C-X-C motif) ligand 3
220723_s_at FLJ21511 0.004075 315.8 7.63 hypothetical protein FLJ21511
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213524_s_at G0S2 0.009023 7490.5 7.54 putative lymphocyte G0/G1 switch gene
201859_at PRG1 0.009023 2434.6 7.51 proteoglycan 1, secretory granule
212531_at LCN2 0.006112 11,606.6 7.42 lipocalin 2 (oncogene 24p3)
202283_at SERPINF1 0.004075 486.2 7.40 serine (or cysteine) proteinase inhibitor, clade F
(alpha-2 antiplasmin, pigment epithelium-derived
factor), member 1
203423_at RBP1 0.004075 2062.5 7.35 retinol binding protein 1, cellular
211506_s_at IL8 0.006112 1262.9 7.26 interleukin 8
206153_at CYP4F11 0.004075 429.6 7.12 cytochrome P450, subfamily IVF, polypeptide 11
38037_at DTR 0.009023 2554.9 7.10 diphtheria toxin receptor (heparin-binding epidermal
growth factor-like growth factor)
209182_s_at DEPP 0.004075 579.9 6.93 decidual protein induced by progesterone
208607_s_at SAA2 0.006112 1443.9 6.92 serum amyloid A2
204614_at SERPINB2 0.004075 5055.3 6.81 serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 2
212646_at KIAA0084 0.004075 1195.6 6.76 KIAA0084 protein
206191_at ENTPD3 0.004075 1342.7 6.69 ectonucleoside triphosphate diphosphohydrolase 3
206421_s_at SERPINB7 0.004075 1235.3 6.63 serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 7
206453_s_at NDRG2 0.004075 1865.9 6.50 NDRG family member 2
209550_at NDN 0.004075 1108.7 6.49 necdin homolog (mouse)
216244_at IL1RN 0.004075 214.6 6.41 interleukin 1 receptor antagonist
203726_s_at LAMA3 0.006112 10,518.0 6.34 laminin, alpha 3
210064_s_at UPK1B 0.004075 1029.1 6.19 uroplakin 1B
218963_s_at HAIK1 0.009023 3314.0 6.12 type I intermediate filament cytokeratin
205403_at IL1R2 0.009023 279.0 6.07 interleukin 1 receptor, type II
206467_x_at TNFRSF6B 0.004075 2452.8 6.06 tumor necrosis factor receptor superfamily,
member 6b, decoy
210118_s_at IL1A 0.004075 3930.9 5.87 interleukin 1, alpha
209546_s_at APOL1 0.009023 933.3 5.84 apolipoprotein L, 1
39402_at IL1B 0.004075 5315.9 5.72 interleukin 1, beta
203535_at S100A9 0.004075 8545.5 5.68 S100 calcium binding protein A9 (calgranulin B)
206662_at GLRX 0.004075 3109.1 5.61 glutaredoxin (thioltransferase)
214841_at FLJ38993 0.009023 260.9 5.46 hypothetical protein FLJ38993
209552_at PAX8 0.009023 477.2 5.44 paired box gene 8
220230_s_at CYB5R2 0.004075 1110.9 5.42 cytochrome b5 reductase b5R.2
206857_s_at FKBP1B 0.004075 1630.9 5.36 FK506 binding protein 1B, 12.6 kDa
204105_s_at NRCAM 0.004075 541.4 5.34 neuronal cell adhesion molecule
205067_at IL1B 0.006112 8008.3 5.31 interleukin 1, beta
209159_s_at NDRG4 0.004075 633.9 5.29 NDRG family member 4
219412_at RAB38 0.009023 3944.4 5.26 RAB38, member RAS oncogene family
209772_s_at CD24 0.004075 3481.1 5.25 CD24 antigen (small cell lung carcinoma cluster
4 antigen)
202267_at LAMC2 0.004075 13,582.0 5.11 laminin, gamma 2
218960_at TMPRSS4 0.009023 1622.0 4.97 transmembrane protease, serine 4
209652_s_at PGF 0.004075 816.1 4.96 placental growth factor, vascular endothelial growth
factor-related protein
200953_s_at CCND2 0.009023 4301.1 4.93 cyclin D2
204249_s_at LMO2 0.004075 357.9 4.78 LIM domain only 2 (rhombotin-like 1)
203234_at UP 0.006112 8821.8 4.75 uridine phosphorylase
212464_s_at FN1 0.004075 15,099.1 4.73 fibronectin 1
207571_x_at ICB-1 0.004075 647.9 4.69 basement membrane-induced gene
203037_s_at KIAA0429 0.004075 2081.5 4.69 KIAA0429 gene product
219697_at HS3ST2 0.004075 816.2 4.65 heparan sulfate (glucosamine) 3-O-sulfotransferase 2
204469_at PTPRZ1 0.004075 204.3 4.58 protein tyrosine phosphatase, receptor-type,
Z polypeptide 1
206893_at SALL1 0.009023 158.6 4.55 sal-like 1 (Drosophila)
204726_at CDH13 0.004075 404.2 4.47 cadherin 13, H-cadherin (heart)
211719_x_at FN1 0.004075 15,762.8 4.45 fibronectin 1
205349_at GNA15 0.006112 2220.4 4.43 guanine nucleotide binding protein (G protein),
alpha 15 (Gq class)
210248_at WNT7A 0.009023 1468.9 4.41 wingless-type MMTV integration site family,
member 7A
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205404_at HSD11B1 0.006112 474.5 4.39 hydroxysteroid (11-beta) dehydrogenase 1
206042_x_at SNURF 0.004075 2260.1 4.39 SNRPN upstream reading frame
210785_s_at ICB-1 0.004075 717.2 4.32 basement membrane-induced gene
204971_at CSTA 0.004075 9892.5 4.32 cystatin A (stefin A)
217983_s_at RNASE6PL 0.004075 5008.8 4.28 ribonuclease 6 precursor
207675_x_at ARTN 0.006112 1546.9 4.28 artemin
214175_x_at RIL 0.004075 1563.6 4.28 LIM domain protein
206584_at MD-2 0.006112 236.6 4.26 MD-2 protein
204542_at STHM 0.009023 2367.7 4.24 sialyltransferase
202957_at HCLS1 0.004075 684.2 4.16 hematopoietic cell-specific Lyn substrate 1
216052_x_at ARTN 0.004075 1361.0 4.15 artemin
209487_at RBPMS 0.006112 1455.5 4.12 RNA-binding protein gene with multiple splicing
202157_s_at CUGBP2 0.006112 559.8 4.06 CUG triplet repeat, RNA binding protein 2
209348_s_at MAF 0.006112 253.0 4.02 v-maf musculoaponeurotic fibrosarcoma oncogene
homolog (avian)
206714_at ALOX15B 0.004075 672.9 3.99 arachidonate 15-lipoxygenase, second type
221854_at (Plakophilin-1-like) 0.009023 2825.0 3.93 ESTs, highly similar to plakophilin 1; Plakophilin-1
(H. sapiens)
209270_at LAMB3 0.004075 15,685.9 3.92 laminin, beta 3
213275_x_at CTSB 0.006112 3187.9 3.92 cathepsin B
219995_s_at FLJ13841 0.004075 345.5 3.89 hypothetical protein FLJ13841
218694_at ALEX1 0.006112 308.8 3.86 ALEX1 protein
209822_s_at VLDLR 0.004075 620.8 3.80 very low density lipoprotein receptor
208650_s_at CD24 0.004075 3639.2 3.80 CD24 antigen (small cell lung carcinoma cluster
4 antigen)
202948_at IL1R1 0.004075 357.3 3.75 interleukin 1 receptor, type I
203722_at ALDH4A1 0.006112 522.2 3.71 aldehyde dehydrogenase 4 family, member A1
212647_at RRAS 0.004075 3810.4 3.66 related RAS viral (r-ras) oncogene homolog
203085_s_at TGFB1 0.004075 2186.8 3.66 transforming growth factor, beta 1
(Camurati–Engelmann disease)
203256_at CDH3 0.006112 8511.9 3.63 cadherin 3, type 1, P-cadherin (placental)
209488_s_at RBPMS 0.009023 1336.4 3.60 RNA-binding protein gene with multiple splicing
204636_at COL17A1 0.004075 3217.5 3.60 collagen, type XVII, alpha 1
217279_x_at MMP14 0.004075 1101.3 3.60 matrix metalloproteinase 14 (membrane-inserted)
203180_at ALDH1A3 0.006112 8439.8 3.58 aldehyde dehydrogenase 1 family, member A3
204952_at C4.4A 0.006112 2024.0 3.51 GPI-anchored metastasis-associated protein homolog
210105_s_at FYN 0.006112 1251.1 3.50 FYN oncogene related to SRC, FGR, YES
204205_at APOBEC3G 0.009023 601.8 3.46 apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3G
212509_s_at (EST) 0.004075 7133.5 3.45 ESTs, weakly similar to hypothetical protein
FLJ22184 (H. sapiens)
219257_s_at SPHK1 0.004075 2472.3 3.43 sphingosine kinase 1
209356_x_at EFEMP2 0.009023 350.2 3.41 EGF-containing fibulin-like extracellular matrix
protein 2
213572_s_at SERPINB1 0.009023 1735.9 3.40 serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 1
266_s_at CD24 0.004075 2423.9 3.37 CD24 antigen (small cell lung carcinoma cluster 4
antigen)
213533_at D4S234E 0.004075 363.9 3.34 DNA segment on chromosome 4 (unique) 234
expressed sequence
211317_s_at CFLAR 0.009023 575.3 3.33 CASP8 and FADD-like apoptosis regulator
217730_at PP1201 0.006112 5059.5 3.32 PP1201 protein
219681_s_at RCP 0.004075 1499.8 3.32 Rab coupling protein
221666_s_at ASC 0.006112 2377.4 3.28 apoptosis-associated speck-like protein containing a
CARD
210495_x_at FN1 0.004075 16,981.8 3.28 fibronectin 1
205011_at LOH11CR2A 0.004075 850.1 3.24 loss of heterozygosity, 11, chromosomal region 2,
gene A
214279_s_at NDRG2 0.006112 642.7 3.22 NDRG family member 2
218319_at PELI1 0.004075 368.9 3.21 pellino homolog 1 (Drosophila)
203817_at GUCY1B3 0.004075 182.1 3.20 guanylate cyclase 1, soluble, beta 3
201645_at TNC 0.004075 1481.5 3.16 tenascin C (hexabrachion)
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202644_s_at TNFAIP3 0.006112 2418.5 3.16 tumor necrosis factor, alpha-induced protein 3
209771_x_at CD24 0.004075 11,152.3 3.15 CD24 antigen (small cell lung carcinoma cluster 4
antigen)
201522_x_at SNRPN 0.004075 4769.3 3.12 small nuclear ribonucleoprotein polypeptide N
210163_at CXCL11 0.009023 109.2 3.11 chemokine (C-X-C motif) ligand 11
200952_s_at CCND2 0.009023 480.1 3.09 cyclin D2
209276_s_at GLRX 0.006112 1825.8 3.09 glutaredoxin (thioltransferase)
212364_at MYO1B 0.004075 1761.4 3.09 myosin IB
202181_at KIAA0247 0.004075 1674.4 3.07 KIAA0247 gene product
216442_x_at FN1 0.004075 17,126.0 3.07 fibronectin 1
211564_s_at RIL 0.009023 1026.5 3.06 LIM domain protein
207836_s_at RBPMS 0.009023 584.8 3.00 RNA-binding protein gene with multiple splicing
201508_at IGFBP4 0.009023 1663.9 3.00 insulin-like growth factor binding protein 4
216379_x_at CD24 0.006112 11,988.5 2.99 CD24 antigen (small cell lung carcinoma cluster 4
antigen)
213293_s_at TRIM22 0.009023 1349.5 2.97 tripartite motif-containing 22
201286_at (SDC1) 0.004075 6578.9 2.97
204638_at ACP5 0.009023 462.8 2.95 acid phosphatase 5, tartrate resistant
218840_s_at FLJ10631 0.009023 514.0 2.94 hypothetical protein FLJ10631
219850_s_at EHF 0.009023 425.3 2.93 ets homologous factor
219305_x_at FBXO2 0.006112 1161.9 2.92 F-box only protein 2
214995_s_at KA6 0.004075 495.5 2.91 induced upon T cell activation
202597_at (EST) 0.006112 5474.0 2.89 ESTs, weakly similar to YYY1_HUMAN Very
very hypothetical protein RMSA-1 (H. sapiens)
213988_s_at SAT 0.004075 6926.0 2.86 spermidine/spermine N1-acetyltransferase
217930_s_at TOLLIP 0.009023 1096.4 2.83 Toll-interacting protein
200986_at SERPING1 0.009023 403.7 2.82 serine (or cysteine) proteinase inhibitor, clade G
(C1 inhibitor), member 1, (angioedema, hereditary)
213272_s_at LOC57146 0.006112 1178.8 2.82 hypothetical protein from clone 24796
200838_at CTSB 0.004075 7430.5 2.80 cathepsin B
219476_at MGC4309 0.004075 1859.1 2.75 hypothetical protein MGC4309
217118_s_at KIAA0930 0.006112 2771.4 2.74 KIAA0930 protein
210001_s_at SOCS1 0.009023 226.8 2.74 suppressor of cytokine signaling 1
204034_at YF13H12 0.004075 7500.9 2.73 protein expressed in thyroid
210397_at DEFB1 0.004075 267.1 2.71 defensin, beta 1
214580_x_at KRT6A 0.009023 9411.7 2.71 keratin 6A
205676_at CYP27B1 0.009023 636.9 2.71 cytochrome P450, subfamily XXVIIB
(25-hydroxyvitamin D-1-alpha-hydroxylase),
polypeptide 1
211862_x_at CFLAR 0.006112 922.0 2.70 CASP8 and FADD-like apoptosis regulator
209126_x_at KRT6B 0.009023 18,599.2 2.69 keratin 6B
200839_s_at CTSB 0.004075 11,534.5 2.63 cathepsin B
160020_at MMP14 0.004075 2631.4 2.60 matrix metalloproteinase 14 (membrane-inserted)
204682_at LTBP2 0.006112 1541.7 2.59 latent transforming growth factor beta binding
protein 2
207196_s_at TNIP1 0.004075 3240.6 2.59 TNFAIP3-interacting protein 1
201631_s_at IER3 0.004075 15,995.3 2.59 immediate early response 3
202074_s_at OPTN 0.004075 1625.1 2.59 optineurin
202073_at OPTN 0.004075 343.1 2.58 optineurin
208651_x_at CD24 0.004075 3203.7 2.58 CD24 antigen (small cell lung carcinoma cluster 4
antigen)
205016_at TGFA 0.004075 2539.3 2.58 transforming growth factor, alpha
212484_at MTVR1 0.004075 1034.8 2.58 mouse mammary tumor virus receptor homolog 1
211552_s_at ALDH4A1 0.006112 690.4 2.57 aldehyde dehydrogenase 4 family, member A1
213924_at MPPE1 0.009023 404.2 2.55 metallophosphoesterase
209723_at SERPINB9 0.009023 655.2 2.54 serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 9
209030_s_at IGSF4 0.004075 273.5 2.53 immunoglobulin superfamily, member 4
37408_at MRC2 0.006112 1120.2 2.53 mannose receptor, C type 2
202643_s_at TNFAIP3 0.006112 934.2 2.52 tumor necrosis factor, alpha-induced protein 3
211031_s_at CYLN2 0.004075 431.3 2.52 cytoplasmic linker 2
209079_x_at PCDHGA1 0.006112 2505.0 2.48 protocadherin gamma subfamily A, 1
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211654_x_at HLA-DQB1 0.009023 478.3 2.47 major histocompatibility complex, class II, DQ
beta 1
218531_at FLJ21749 0.006112 1382.9 2.45 hypothetical protein FLJ21749
209369_at ANXA3 0.009023 2942.1 2.44 annexin A3
218451_at CDCP1 0.006112 2332.9 2.43 CUB domain-containing protein 1
40016_g_at KIAA0303 0.004075 798.8 2.43 KIAA0303 protein
211066_x_at PCDHGC3 0.006112 2531.6 2.41 protocadherin gamma subfamily C, 3
205789_at CD1D 0.004075 159.7 2.40 CD1D antigen, d-polypeptide
214632_at NRP2 0.004075 211.7 2.38 neurophilin 2
211824_x_at DEFCAP 0.009023 155.8 2.38 death effector filament-forming Ced-4-like
apoptosis protein
209508_x_at CFLAR 0.004075 538.9 2.36 CASP8 and FADD-like apoptosis regulator
205375_at MDFI 0.009023 775.8 2.36 MyoD family inhibitor
205180_s_at ADAM8 0.006112 637.6 2.36 a disintegrin and metalloproteinase domain 8
209637_s_at RGS12 0.006112 738.0 2.33 regulator of G-protein signaling 12
217858_s_at ALEX3 0.006112 388.8 2.32 ALEX3 protein
38149_at KIAA0053 0.009023 264.2 2.32 KIAA0053 gene product
220054_at IL23A 0.004075 376.0 2.31 interleukin 23, alpha subunit p19
221756_at MGC17330 0.004075 479.7 2.31 hypothetical protein MGC17330
220753_s_at CRYL1 0.009023 871.3 2.30 crystallin, lambda 1
635_s_at PPP2R5B 0.004075 513.4 2.28 protein phosphatase 2, regulatory subunit B (B56),
beta isoform
205717_x_at PCDHGC3 0.004075 1726.8 2.28 protocadherin gamma subfamily C, 3
201249_at SLC2A1 0.004075 331.5 2.27 solute carrier family 2
(facilitated glucose transporter), member 1
204620_s_at CSPG2 0.009023 239.3 2.27 chondroitin sulfate proteoglycan 2 (versican)
206355_at GNAL 0.006112 152.8 2.26 guanine nucleotide binding protein (G protein),
alpha activating activity polypeptide, olfactory type
211316_x_at CFLAR 0.006112 995.8 2.26 CASP8 and FADD-like apoptosis regulator
201287_s_at SDC1 0.004075 10,943.8 2.26 syndecan 1
64486_at CORO1B 0.004075 2661.1 2.26 coronin, actin-binding protein, 1B
221757_at MGC17330 0.004075 740.2 2.25 hypothetical protein MGC17330
209260_at SFN 0.006112 10,326.6 2.23 stratifin
212736_at BC008967 0.009023 260.1 2.23 hypothetical gene BC008967
205973_at FEZ1 0.004075 259.5 2.22 fasciculation and elongation protein zeta 1 (zygin I)
202744_at SLC20A2 0.009023 733.0 2.22 solute carrier family 20 (phosphate transporter),
member 2
219267_at GLTP 0.006112 1013.0 2.21 glycolipid transfer protein
203504_s_at ABCA1 0.009023 464.4 2.21 ATP-binding cassette, subfamily A (ABC1),
member 1
212956_at KIAA0882 0.004075 492.0 2.19 KIAA0882 protein
214435_x_at RALA 0.006112 1224.3 2.19 v-ral simian leukemia viral oncogene homolog A
(ras related)
217867_x_at BACE2 0.004075 2377.9 2.16 beta-site APP-cleaving enzyme 2
204447_at ProSAPiP1 0.009023 429.0 2.15 ProSAPiP1 protein
215411_s_at C6orf4 0.009023 1881.8 2.14 chromosome 6 open reading frame 4
204137_at TM7SF1 0.006112 285.9 2.13 transmembrane 7 superfamily member 1
(up-regulated in kidney)
121_at PAX8 0.009023 2773.5 2.13 paired box gene 8
206197_at NME5 0.004075 192.2 2.12 nonmetastatic cells 5, protein expressed in
(nucleoside-diphosphate kinase)
219489_s_at RHBDL2 0.009023 5239.4 2.10 rhomboid, veinlet-like 2 (Drosophila)
208816_x_at ANXA2P2 0.004075 6962.6 2.10 annexin A2 pseudogene 2
219368_at NAP1L2 0.009023 64.5 2.07 nucleosome assembly protein 1-like 2
206581_at BNC 0.006112 549.1 2.07 basonuclin
203725_at GADD45A 0.004075 4735.3 2.07 growth arrest and DNA-damage-inducible, alpha
209912_s_at KIAA0415 0.006112 203.7 2.07 KIAA0415 gene product
216383_at - 0.009023 1036.4 2.07
204334_at KLF7 0.009023 671.2 2.06 Kruppel-like factor 7 (ubiquitous)
209931_s_at FKBP1B 0.009023 356.2 2.06 FK506 binding protein 1B, 12.6 kDa
204319_s_at RGS10 0.004075 1327.2 2.05 regulator of G-protein signaling 10
219202_at FLJ22341 0.009023 693.4 2.04 hypothetical protein FLJ22341
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217971_at MAP2K1IP1 0.004075 928.0 2.03 mitogen-activated protein kinase kinase 1-interacting
protein 1
203686_at MPG 0.009023 1145.1 2.03 N-methylpurine-DNA glycosylase
37152_at PPARD 0.006112 1428.0 2.02 peroxisome proliferative activated receptor, delta
214104_at (FLJ34550) 0.009023 327.4 2.02 H. sapiens cDNA FLJ34550 fis,
clone HLUNG2009303, mRNA sequence
202180_s_at MVP 0.004075 1852.8 2.00 major vault protein
A.D. Santin et al. / Virology 331 (2005) 269–291282vitro expansion conditions may have modified gene
expression, we performed immunohistochemical analysis
of CDKN2A/p16 and PTGES protein expression on
formalin-fixed tissue from all uncultured primary surgicalFig. 2. Quantitative RT-PCR and microarray expression analysis of CDKN2A, v-M
NCK. qRT-PCR samples were run in duplicate. The results of one experiment arspecimens of CVX and NCK tested in the gene
expression analysis (Table 4). As representatively shown
in Fig. 4, heavy nuclear and cytoplasmic staining for p16
protein expression was noted in all squamous, adenosqu-yb, PTGES, and TOP2A genes differentially expressed between CVX and
e shown and are representative of two separate studies with similar results.
Fig. 3. Flow cytometric analysis of CDKN2A/p16 staining of CVX primary and NCK cell lines. Representative histograms show CDKN2A/p16 data in dashed
lines while isotype control MAb profiles are shown in solid lines. NCK (A) showed negative staining for CDKN2A/p16 while CVX 1 (B; squamous cervical
cancer), CVX 2 (C; adenosquamous cervical cancer), and CVX 7 (D; adenocarcinoma) all showed strong positivity for CDKN2A/p16 (P b 0.01 by Student’s
t test).
A.D. Santin et al. / Virology 331 (2005) 269–291 283amous, and adenocarcinoma specimens that overexpressed
the CDKN2A gene and its gene product by microarray
and flow cytometry, respectively. In contrast, negative
(i.e., score 0) staining was found in all NCK samples
tested by immunohistochemistry (Table 4 and Fig. 4). As
presented in Table 4 and representatively shown in Fig. 5,
similar results were obtained when immunohistochemistry
was carried out to demonstrate PTGES expression on
tumor cells. Furthermore, focal intense or diffuse intense
staining for CDKN2A/p16 and PTGES protein expression
(i.e., score 2+ and 3+) was noted in the majority of the
separate set of archival CVX specimens use for compar-
ison (CVX-12 to CVX-22, Table 4). Thus, these data
generated on an independent set of invasive cervical
cancer specimens confirmed p16 and PTGES protein
expression as two consistently positive markers to identify
HPV-infected cervical cancer cells.Discussion
The management of disseminated carcinoma of the
cervix no longer amenable to control with surgery or
radiation therapy has not improved significantly with
modern chemotherapy; the 1-year survival among patientswith such refractory disease remains at a dismal 10–15%. A
deeper molecular understanding of host interactions with
cervical carcinogenic factors and novel therapeutic strat-
egies effective to prevent disease progression following
first-line treatment remain desperately needed.
Large-scale gene expression analysis such as high-
density oligonucleotide and cDNA microarrays represents
a powerful new tool that has the potential to identify a
number of differentially expressed genes in HPV-infected
cervical cancers compared to normal cervical keratinocytes.
These analyses may therefore lay the groundwork for future
studies testing some of these markers for clinical utility in
the diagnosis and eventually the treatment of this disease.
This report represents the first communication of an
investigation involving the genome-wide examination of
differences in gene expression between primary HPV16 and
HPV18-infected CVX and normal cervical epithelial cells
(NCK). In this regard, although the possible changes in gene
expression related to the removal of normal and cervical
cancer cells from their microenvironment remains unknown,
in this study we have used short-term primary CVX and
NCK cultures (to minimize the risk of a selection bias
inherent in any long-term in vitro growth) to study differ-
ential gene expression in highly enriched and homogeneous
populations of cervical epithelial cells. In this work, cancer
Table 4
p16 and PTGES immunostaining in normal cervix keratinocytes and cancer
Case Histology p16/CDKN2A PTGES
NCK-1 Squamous  
NCK-2 Squamous  
NCK-3 Squamous  
NCK-4 Squamous  
CVX-1 Squamous ++ +++
CVX-2 Adenosquamous ++ ++
CVX-3 Squamous ++ ++
CVX-4 Squamous ++ +++
CVX-5 Squamous ++ ++
CVX-6 Squamous ++ ++
CVX-7 Adenocarcinoma ++ +++
CVX-8 Adenocarcinoma ++ ++
CVX-9 Adenosquamous ++ +
CVX-10 Adenosquamous ++ ++
CVX-11 Adenocarcinoma ++ ++
CVX-12 Squamous ++ ++
CVX-13 Adenosquamous ++ ++
CVX-14 Squamous ++ ++
CVX-15 Squamous ++ +
CVX-16 Adenocarcinoma ++ ++
CVX-17 Adenosquamous + +
CVX-18 Squamous ++ ++
CVX-19 Squamous ++ +
CVX-20 Squamous ++ +++
CVX-21 Squamous ++ ++
CVX-22 Squamous ++ ++
A.D. Santin et al. / Virology 331 (2005) 269–291284cells derived from early stages invasive squamous, adenos-
quamous, and adenocarcinoma cervical tumors, which
represent all the common histological types of cervical
cancer, were included in the gene expression analysis.
We found that hierarchical clustering of the samples and
gene expression levels within the samples led to theFig. 4. Representative immunohistochemical staining for CDKN2A/p16 markers o
(A) showed negative staining for CDKN2A/p16 while CVX 1 (B; squamous cerv
adenocarcinoma) showed diffuse staining for CDKN2A/p16. Original magnificatiunambiguous separation of CVX and NCK. Of 1354 genes
showing greater than twofold up- and down-regulation and a
majority of detection = present calls in more than half of the
samples, we identified 505 genes that were statistically
significant by the WRS test at alpha = 0.01, with a one-sided
upper 99% confidence limit of 20.48 false discoveries
(4.05%). Of the 505 genes with WRS P b 0.01, 240
exhibited up-regulation and 265 exhibited down-regulation
in CVX compared to NCK. The known function of some of
these genes may provide insights in the biology of cervical
tumors while others may prove to be useful diagnostic and
therapeutic markers against CVX.
For example, the expression of genes required for
progression through the cell cycle is highly modulated
through a regulatory axis containing the E2F transcription
factor and retinoblastoma (pRb) tumor suppressor protein
families. Of interest, the cyclin-dependent kinase inhibitor
2A (CDKN2A) gene was found to be one of the most highly
differentially expressed genes in CVX, with over 10-fold
up-regulation relative to NCK. Importantly, CDKN2A gene
is a putative oncosuppressor gene encoding two unrelated
proteins, both cellular growth inhibitors, in different reading
frames (Quelle et al., 1995; Sano et al., 2002). One is p16,
which regulates retinoblastoma protein (pRb)-dependent G1
arrest; and the second is p14ARF, which blocks MDM2-
induced p53 degradation resulting in an increase in p53
levels that leads to cell cycle arrest (Quelle et al., 1995;
Sano et al., 2002). Because high-risk HPV E6 and E7
transforming oncoproteins are able to inactivate p53 and Rb
tumor suppressor function, the marked overexpression of
the CDKN2A gene may likely be a negative feedback
phenomenon resulting from the functional inactivation off three paraffin-embedded CVX specimens and one NCK specimen. NCK
ical cancer), CVX 2 (C; adenosquamous cervical cancer), and CVX 7 (D;
on 400.
Fig. 5. Representative immunohistochemical staining for PTGES markers of one paraffin-embedded CVX specimen and one NCK specimen. NCK (left panel)
showed negative staining for PTGES while CVX 1 (right panel) showed diffuse intense positivity for PTGES. Original magnification 400.
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2002). Consistent with this hypothesis, an inverse relation-
ship between the expression of p16 and p14ARF proteins
and the presence of normal Rb and p53 in human cancer
cells (Quelle et al., 1995; Sano et al., 2002), as well as an
association between HPV infection and overexpression of
p16 and p14ARF in cervical carcinoma and dysplasia, has
been recently demonstrated (Khleif et al., 1996). Taken
together, these data suggest that CDKN2A gene over-
expression may represent a consistent genetic anomaly of
HPV-infected cervical cancer cells. Furthermore, these
results also suggest that CDKN2A gene products such as
p16 and p14ARF (data not shown) may have significant
potential as specific biomarkers to be targeted for diagnostic
and/or prognostic purposes in cervical cancer (Murphy et
al., 2003). Protein expression data obtained by flow
cytometry with anti-p16 antibody on primary CVX cell
lines and by immunohistochemistry on uncultured cervical
tumor blocks further support this view.
In HPV-infected cervical tumors, the functional inacti-
vation of pRb by E7 binding is thought to allow the
accumulation of members of the E2F family of cellular
transcription factors (Khleif et al., 1996), which signal the
synthesis of enzymes required to drive the cell into S phase.
In this model, E2F1 overexpression leads to an inhibition of
cyclin D1-dependent kinase activity and induces the over-
expression of the CDKN2A gene expression products
(Khleif et al., 1996). Interestingly, high-risk HPV E7
oncoproteins have been previously shown to deregulate B-
myb expression, a cell-cycle-regulated transcription factor
the expression of which is also directed by an E2F-
dependent transcriptional mechanism (Lam et al., 1994).
Because B-myb is known to play an essential role in cell
cycle progression (Joaquin and Watson, 2003), and expres-
sion of B-myb may bypass p53-induced p21-mediated G1
arrest (Lin et al., 1994), activation of the B-myb oncogene
by E7 (Lam et al., 1994) may significantly contribute to the
mitogenic activity of E7 in HPV-infected cervical tumors.
Furthermore, because B-myb overexpression has been
shown to overcome growth arrest associated with terminal
differentiation (Bies et al., 1996) as well as cause a
differentiation block in the presence of differentiation
factors in human malignancies (Raschella et al., 1995), wespeculate that B-myb overexpression in cervical cancer
might be also involved in the rescue from senescence of
HPV-transformed cervical cells as well as in the induction of
a more aggressive cervical cancer phenotype. Our gene
expression profile results are consistent with this view in
that CDKN2A, E2F1, and B-myb genes were all found
highly differentially expressed in HPV-infected tumors
when compared to NCK.
Genomic imprinting is a mechanism by which a number
of genes throughout the genome are monoallelically
expressed according to their parental origin. Human
mesoderm-specific transcript (MEST) is an imprinted gene
expressed from the paternal allele and located on chromo-
some 7q32 (Pedersen et al., 1999). In this study, MEST was
found to be one of the most highly differentially expressed
gene in CVX compared to NCK. Of interest, loss of
imprinting (LOI) or biallelic expression has been recently
proposed as an important epigenetic mechanism for tumori-
genesis in several human cancers including cervical cancer
(Douc-Rasy et al., 1996; Kohda et al., 2001; Pedersen et al.,
1999). To the best of our knowledge, however, MEST has
not been previously linked to this disease. Importantly, in
vitro treatment of tumor cells with 5-aza-2-deoxycytidine, a
specific inhibitor of cytosine DNA methyl-transferase, has
been reported to reverse LOI of insulin-like growth factor 2
(IGF2) and H19 genes, highlighting the potential of
targeting aberrant tumor imprinting for therapeutic inter-
vention (Barletta et al., 1997). Although the function of the
MEST gene product is unknown, the putative protein shares
homology with the a/h hydrolase family, which also
includes the lysosomal enzyme cathepsin A (Kaneko-Ishino
et al., 1995). This may suggest a possible role of MEST in
the degradation of the extracellular matrix in the invasive
state of cervical tumors.
Forkhead box (FOX) proteins constitute an extensive
family of transcription factors, which share homology in
the winged helix DNA binding domain (Clark et al., 1993)
and which have been shown to play important roles in
regulating the expression of genes involved in cell growth,
proliferation, and transformation (Kaestner et al., 2000).
Elevated FOXM1 levels have been found in numerous
human tumors (Korver et al., 1997; Yao et al., 1997; Ye et
al., 1997), suggesting that FOXM1 is required for cellular
A.D. Santin et al. / Virology 331 (2005) 269–291286proliferation in human cancer cells. However, the func-
tional importance of this gene family in normal keratino-
cyte physiology and cervical cancer remains poorly
understood. In our analysis, the FOXM1 gene was found
to be one of the most highly differentially expressed genes
in CVX, with over sevenfold up-regulation relative to
NCK. Because FOXM1 overexpression in human kerati-
nocytes has been suggested to contribute to cell trans-
formation and to be one of the mechanisms exerting a
mitogenic effect on basal keratinocytes, leading to the
development of basal cell cancer (The et al., 2002), it
seems likely that FOXM1 overexpression may contribute
to HPV-induced keratinocyte transformation and the
development of cervical cancer. Although further work
will be necessary to validate this hypothesis, inhibition of
FOXM1 function might be a possible target for cervical
anticancer therapies (Ruiz et al., 2002).
Prostaglandin E2 synthase (PTGES) is a stimulus-
inducible enzyme that functions downstream of cyclo-
oxygenase (COX-2) in the PGE2-biosynthetic pathway.
The biological actions of PGE2 have been attributed to its
interaction with G-protein-coupled seven-transmembrane
domain receptors, which belong to the rhodopsin super-
family of serpentine receptors (Murakami et al., 2002).
Substantial clinical, genetic, and biochemical evidence
suggests that PGE2 plays a crucial role in the development
of human tumors such as colorectal cancer (Murakami et al.,
2002). In addition, elevated levels of PGE2 and COX-2
proteins have been detected in a variety of human epithelial
tumors including cervical cancers (Sales et al., 2001). In this
regard, enhanced synthesis of PGE2 resulting from up-
regulated COX-2 gene expression has been shown to
stimulate gene transcription, inhibit apoptosis, and increase
the metastatic potential of epithelial cells by promoting
angiogenesis (Murakami et al., 2002). Consistent with the
role played by PGE2 in the development and progression of
a variety of human tumors, in this study PGES-1 was found
to be one of the most highly differentially expressed gene in
CVX compared to NCK. Importantly, tumors secreting large
amounts of PGE2 significantly suppress cellular immunity
in human cancer patients (Balch et al., 1984; Huang et al.,
1998). These findings, combined with our data, support the
hypothesis that PGE2 overexpression by cervical cancer
cells may play an important negative role during tumor–
host–immune system interactions and thus contribute to
immunological evasion by HPV-infected tumors. Impor-
tantly, nonsteroidal anti-inflammatory drugs, which inhibit
COX-2, have been reported to be effective novel therapies
to reduce the incidence of colorectal cancer (Murakami et
al., 2002). Taken together, these data suggest that inves-
tigations to determine whether PGES-1 may represent a
novel pharmacological target for preventing or treating
cervical cancer would be worthwhile.
Topoisomerase II (TOP2A) is a nuclear enzyme that
modulates DNA topology during several metabolic pro-
cesses and is required for the segregation of daughterchromosomes at the end of replication (Pommier, 1993). In
addition, TOP2A gene expression in human tumor cells is
clinically and pharmacologically important, being targeted
by a number of anticancer agents, including etoposide,
mitoxantrone, and doxorubicin, which are termed topoiso-
merase II poisons (Pommier, 1993). A relationship between
expression of topoisomerase II isoforms and intrinsic
sensitivity to TOP2A inhibitors has been reported in several
human tumors (Asano et al., 1996; Houlbrook et al., 1995;
Pommier, 1993). In our study, TOP2A gene was found to be
one of the most highly differentially expressed gene in CVX
with over fivefold up-regulation relative to NCK. These data
are consistent with a previous report showing high
expression of the TOP2A gene product in invasive
squamous cervical cancer (Gibbons et al., 1997). Of interest,
a functional interaction between TOP2A and retinoblastoma
protein has been recently described in which underphos-
phorylated Rb inhibits TOP2A activity (Bhat et al., 1999).
We are therefore tempting to speculate that, in analogy to
other previously described genes found highly overex-
pressed in HPV-infected CVX compared to NCK, functional
inactivation of pRb by E7 binding may result in the marked
overexpression of the TOP2A gene detected by gene
expression profiling. Whatever the mechanism involved in
TOP2A overexpression in HPV16/18-infected cervical
cancer, these results suggest that future work testing the
clinical efficacy of DNA topoisomerase II inhibitors in
invasive cervical cancer refractory to standard treatment
modalities might be beneficial.
CD97 is a dimeric glycoprotein belonging to the
secretin-receptor superfamily and is abundantly expressed
in cells of hematopoietic origin (Jaspars et al., 2001). CD97
has an extended extracellular region with several N-
terminal epidermal growth factor (EGF)-like domains,
which mediate binding to decay accelerating factor (DAF/
CD55), a regulatory protein of the complement cascade
(Hamann et al., 1996; Jaspars et al., 2001). Of interest, CD97
was found to be one of the most highly differentially
expressed genes in CVX when compared to NCK. Recently,
high expression of CD97 has been reported in human
anaplastic thyroid carcinomas and poorly differentiated
adenocarcinomas of the gastrointestinal tract (Aust et al.,
1997; Jaspars et al., 2001). To the best of our knowledge,
however, CD97 has not been previously linked to cervical
cancer. Despite the fact that the biological function of CD97
is still unknown, accumulating data on its structure and
molecular characteristics suggest a potential function asso-
ciated with adhesion and signal transduction (Jaspars et al.,
2001). Furthermore, it is likely that binding of CD55 to
CD97 overexpressing tumor cells might favor tumor cell
survival by protecting them from complement-dependent
lysis, thus enhancing the potential for immunological
evasion.
Cyclins are a family of molecules that control the cell
cycle by associating with activating cyclin-dependent
kinases (cdks). Cyclin B1 is a component of the cdc2 that
Table 5
Patient characteristics
Case Age Stage Histology HPV type Treatment
CVX-1a 54 IB Squamous 16 Surgery
CVX-2 32 IB Adenosquamous 16 Surgery
CVX-3 51 IB Squamous 16 Radiation
CVX-4 49 IB Squamous 16 Surgery
CVX-5 44 IIA Squamous 16 Surgery
CVX-6 43 IB Squamous 16 Surgery
CVX-7 26 IB Adenocarcinoma 18 Surgery
CVX-8 46 IB Adenocarcinoma 18 Surgery
CVX-9 31 IB Adenosquamous 18 Surgery
CVX-10 36 IB Adenosquamous 18 Surgery
CVX-11 49 IB Adenocarcinoma 18 Surgery
a Tumor cell lines were derived from biopsy obtained from the cervix in all
patients.
A.D. Santin et al. / Virology 331 (2005) 269–291 287it is normally expressed at very low level in the cell nucleus.
It appears at S phase, peaks in expression at G2/M, and it is
rapidly degraded at the end of mitosis by ubiquitination and
targeting to the proteasome (King et al., 1994). Studies in
different human tumors and cell lines including breast, lung,
colorectal, lymphoma, leukemia, and melanoma have
detected overexpression of cyclin B1 at both protein and
mRNA level (Finn, 2003). Consistent with these observa-
tions, a high differential expression of cyclin B1 was
consistently found in all CVX tested when compared to
NCK. The abnormal cyclin B1 level previously found in
human tumors has been shown to correlate with either
mutation or deletion of p53 function (Yu et al., 2002). Thus,
it is likely that the well-established inactivation of p53
function by the tight binding to HPV16/18 E6 oncoproteins
in cervical cancer may be responsible for cyclin B1
overexpression. Of interest, cyclin B1 has recently been
identified as a shared human epithelial tumor-associated
antigen recognized by T cells (Finn, 2003; Kao et al., 2001).
Furthermore, cyclin B1 overexpression in human tumors
was found to correlate with the presence of cyclin B1-
specific memory T cell responses in cancer patients’
peripheral blood, suggesting that T cells may be directly
primed in vivo (Finn, 2003; Kao et al., 2001). Taken
together, these data suggest that, in addition to high-risk
HPV E6 and E7 oncoproteins (Santin et al., 1999, 2002), the
aberrant overexpression and overabundance of cyclin B1-
derived peptides in tumor HLA class I molecules (Finn,
2003; Kao et al., 2001) might be exploited as adjunctive
targets for therapeutic vaccine development against cervical
cancer.
A large number of down-regulated (at least twofold)
genes in CVX versus NCK such as transforming growth
factor, beta 1, transforming growth factor alpha, CFLAR,
serine proteinase inhibitors (SERPING1 and SERPINF1),
cadherin 13, protease inhibitor 3, keratin 16, and tissue
factor pathway inhibitor-2 (TFPI-2) have been identified in
our analysis. Some of these genes are known tumor
suppressor genes or encode proteins important for epithelial
tissue homeostasis or that have been previously implicated
in apoptosis, proliferation, adhesion, or tissue maintenance.
Because of space limitations, we will not comment further
upon the cluster of genes that showed down-regulation of
the transcripts in invasive tumors.
In conclusion, several CVX-restricted markers have been
identified through our analysis. Some of these genes have
been recently identified as up-regulated in other microarrays
reports (for example, v-myb, TOP2A, diubiquitin, MMP-11)
(Alazawi et al., 2002; Chang and Laimins, 2000; Chen et al.,
2003; Nees et al., 2001; Oh et al., 2001), further validating
our criteria for determination of differentially expressed
genes, but most of the genes detected represent novel
findings. Many of these up-regulated genes are likely to
represent the result of aberrant activation of a number of
dominant pathways that derive from the functional inacti-
vation of pRb and p53 proteins by HPV oncoproteins. It isour hope that some of the cervical tumor markers identified
in this work may be readily used for early detection of
dysplasia and/or disease recurrence as well as the develop-
ment of novel therapies against cervical cancer refractory to
standard treatment modalities.Materials and methods
Establishment of CVX and NCK primary cell lines
A total of 15 primary cell lines (i.e., 11 CVX and 4 NCK)
were established after sterile processing of the samples from
surgical biopsies as previously described (Santin et al.,
1999). Fresh tumor biopsies from patients diagnosed with
frankly invasive stage IB–IIA cervical cancer (staged
according to the F.I.G.O. operative staging system) were
obtained at the time of surgery and/or staging through the
Gynecologic Oncology Division and the Pathology Depart-
ment, UAMS, under approval of the Institutional Review
Board. Patient characteristics are described in Table 5.
Radical abdominal hysterectomy and lymph node dissection
for invasive cervical cancer were performed in all patients
but one. Normal keratinocyte control samples (i.e., four
primary keratinocyte cultures) were obtained from cervical
biopsies of hysterectomy specimens from women diagnosed
with benign disease and a previous report of a normal
cytological evaluation. All fresh primary cell lines were
collected for RNA extraction at a confluence of 60–80%
after a minimum of two to a maximum of 15 passages in
vitro without significant differences in the number of
passages between normal cells and cancer cell lines. Purity
of fresh cultures was tested by morphology, immunohis-
tochemistry staining, and/or flow cytometry with antibodies
against cytokeratins. Only primary cultures that had at least
90% viability and contained N99% epithelial cells were used
for total RNA extraction. No patient received radiation
therapy or chemotherapy before surgery or tissue biopsy.
Briefly, single-cell suspensions were obtained by processing
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temperature. Viable tumor tissue was mechanically minced
in RPMI 1640 to portions no larger than 1–3 mm3 and
washed twice with RPMI 1640. The portions of minced
tumor were then placed into 250 ml flasks containing 30
ml of enzyme solution [0.14% collagenase type I (Sigma,
St. Louis, MO) and 0.01% DNAse (Sigma, 2000 kU/mg)]
in RPMI 1640, and incubated on a magnetic stirring
apparatus either for 2 h at 37 8C or overnight at 4 8C.
Enzymatically dissociated tumor was then filtered through
150 Am nylon mesh to generate a single cell suspension.
The resultant cell suspension was then washed twice in
RPMI 1640 plus 10% human AB serum (Gemini Bio-
products, Calabasas, CA) before being seeded in tissue
culture flasks in serum-free keratinocyte medium, supple-
mented with 5 ng/ml epidermal growth factor and 35–50
Ag/ml bovine pituitary extract (Invitrogen, Grand Island,
NY) at 37 8C.
HPV genotyping
Sequence-specific primers for the E7 oncoproteins were
used to confirm or exclude by PCR the presence of the
HPV16 and/or HPV18 genotype in the 11 primary CVX and
in the four primary NCK cultures used in this study. Briefly,
for HPV16, 0.1–1 Ag of each genomic DNA sample was
amplified in a 50-Al reaction containing 0.3 AM of each of
the individual primers (HPV16 E7: F 5V-ATG GAG ATA
CAC CTA CAT TGC-3V; R 5V-GGT TTC TGA GAA CAG
ATG GGG C-3V) in the presence of 1 PCR buffer, 2.5 AM
MgCl2, 0.8 AM dNTPs, and 0.025U/Al U AmpliTaq DNA
polymerase (Applied Biosystems, Foster City, CA). Ampli-
fications were performed in the Applied Biosystems
GeneAmp PCR System 2700 (Applied Biosystems) at 95
8C for 3 min, followed by 35 cycles of 95 8C for 30 s, 60 8C
for 30 s, 72 8C for 1 min, and a final extension of 72 8C for
7 min. For HPV18, 0.1–1 Ag of each genomic DNA sample
was amplified in a 50-Al reaction containing 0.25 AM of
each of the individual primers (HPV18 E7: F 5V-CAT GGA
CCT AAG GCA ACA TTG C-3V; R 5V-CTG CTG GGA
TGC ACA CCA CGG-3V) in the presence of 1 PCR
buffer, 2.0 AM MgCl2, 1 AM dNTPs, and 0.025U/Al U
AmpliTaq DNA polymerase (Applied Biosystems). Ampli-
fications were performed in the Applied Biosystems
GeneAmp PCR System 2700 (Applied Biosystems) at 95
8C for 5 min, followed by 35 cycles of 95 8C for 1 min, 63
8C for 30 s, 72 8C for 1 min, and a final extension of 72 8C
for 7 min. The PCR products were stored at 4 8C before
electrophoresis on a 2% agarose gel. Beta-tubulin gene
amplification with the following primers: F 5V-CGC ATC
AAC GTG TAC TAC AA-3V, R 5V-TAC GAG CTG GTG
GAC TGA GA-3V(0.25 AM of each primer), was used as a
positive internal control. SiHa (HPV-16) and HeLa (HPV-
18) cervical carcinoma cell lines DNA were used as a
positive external control. HT-3 (HPV-negative) cell line
DNA and a water template were used as negative controls.As described in Table 5, all 11 primary cervical cancers
were shown to harbor HPV16 or HPV18. In contrast, none
of the four primary cervical keratinocyte cultures was found
infected with HPV16 or HPV18 (data not shown).
RNA purification and microarray hybridization and
analysis
Detailed protocols for RNA purification, cDNA syn-
thesis, cRNA preparation, and hybridization to the Affyme-
trix Human U133A GeneChip microarray were performed
according to the manufacturer’s protocols, as reported
previously (Ross et al., 2003).
Data processing
All data used in our analyses were derived from
Affymetrix 5.0 software. GeneChip 5.0 output files
contain for each probe set a continuous-valued bsignalQ
that represents the difference between the intensities of the
sequence-specific perfect-match probes and corresponding
mismatch probes in each set, and a bdetectionQ classi-
fication of each signal as present, marginal, or absent as
determined by the GeneChip 5.0 algorithm. Gene arrays
were scaled to an average signal of 1500 for calculation
of each probe set’s mean fold change in signal between
CVX and NCK samples. For statistical assessment of
differential expression, each array was normalized to give
a mean of 0 and variance of 1 after log2-transformation of
signal calls.
Gene expression data analysis
Statistical analyses of the data were performed with the
software packages SPSS10.0 (SPSS, Chicago, IL). Genes
were selected for analysis based on detection and fold
change. In each comparison, genes having bpresentQ
detection calls in more than half of the samples in the
overexpressed gene group (i.e., at least 6 out of 11 tumor
samples or in at least three out of four normal samples) were
retained for statistical analysis if they showed greater than
twofold change between groups. A total of 1354 genes were
retained and subsequently subjected to the Wilcoxon rank-
sum (WRS) test at alpha = 0.05. One-sided upper 99%
confidence limits (99% confidence maxima) on the number
and percent of false discoveries at each P value were
calculated numerically by applying Newton’s method to the
null-hypothesis distribution in the manner described by
Siegel et al. (2004).
Gene cluster/Treeview
Hierarchical clustering via the average linkage method
using the centered correlation metric was used (Ross et al.,
2003; Zhan et al., 2002). The dendrogram was constructed
with a subset of genes from 22,215 probe sets present on the
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the 15 samples, and were thus most informative. For the
hierarchical clustering shown in Fig. 1, only genes sig-
nificantly expressed and whose average change in expres-
sion level was at least twofold were chosen. The expression
value of each selected gene was renormalized to have a
mean of zero.
Quantitative real-time PCR
q-RT-PCR was performed with an ABI Prism 7000
Sequence Analyzer using the manufacturer’s recommended
protocol (Applied Biosystems) to validate differential
expression of selected genes in samples from all primary
cell lines (11 CVX and 4 NCK). Each reaction was run in
triplicate. The comparative threshold cycle (CT) method was
used for the calculation of amplification fold as specified by
the manufacturer. Briefly, 5 Ag of total RNA from each
sample was reverse transcribed using SuperScript III first-
strand cDNA synthesis (Invitrogen, Carlsbad, CA). Ten
microliters of reverse-transcribed RNA samples (from 500
Al of total volume) was amplified by using the TaqMan
Universal PCR Master Mix (Applied Biosystems) to
produce PCR products specific for cyclin-dependent kinase
inhibitor 2A (CDKN2A/p16), v-Myb, PTGES, and TOP2A.
Primers specific for 18S ribosomal RNA and empirically
determined ratios of 18S competimers (Applied Biosystems)
were used to control for the amounts of cDNA generated
from each sample. Primers for v-Myb, PTGES, and TOP2A
were obtained from Applied Biosystems as assay on
demand products. Assays ID were Hs00231158_m1 (v-
Myb), Hs00610420_m1 (PTGES), and Hs00172214_m1
(TOP2A). CDKN2A/p16 primers sequences were the
following (F 5V-CCC AAA CGC ACC GAA TAG TTA C-
3V; R 5V-ATT CCA ATT CCC CTG CAA ACT-3V).
Differences in CVX from NCK in the q-RT-PCR expression
data were tested using the Kruskal–Wallis nonparametric
test. Spearman rank correlations were used to estimate the
degree of association between the microarray and q-RT-PCR
data for each of these four genes.
Flow cytometry
To validate microarray data on primary CVX and NCK at
the protein level, CDKN2A/p16 expression was evaluated
by flow cytometric analysis. Briefly, primary cells were
harvested, washed, and fixed with 2% paraformaldehyde in
PBS for 20 min at room temperature. Cells were then
washed and permeabilized by incubation in PBS plus 1%
BSA and 0.5% saponin (S-7900, Sigma) for 15 min at room
temperature. Cells were stained with FITC-conjugated p16
antibody reagent set [anti-p16 (IgG1K) and isotype control
antibodies (mouse IgG1K)] obtained from BD PharMingen
(San Diego, CA). After staining, cells were washed twice
with PBS plus 1% BSA and 0.5% saponin, once with PBS
plus 0.5% BSA, and fixed a second time with 2%paraformaldehyde in PBS. Analysis was conducted with a
FACScan, utilizing Cell Quest software (Becton Dickinson,
San Jose, CA).
CDKN2A/p16 immunostaining of formalin-fixed tumor
tissues
To evaluate whether the differential CDKN2A/p16
expression detected by flow cytometry on primary CVX
cell lines was comparable to the expression of CDKN2A/
p16 of cervical tumors from which the primary cell lines
were derived, protein expression was evaluated by standard
immunohistochemical staining on formalin-fixed tumor
tissue from all surgical specimens (i.e., 11 CVX and 4
NCK controls). In addition, to validate our findings on a
separate independent set of invasive cervical cancers,
archival blocks derived from a further 10 patients harboring
invasive cervical cancer were tested for CDKN2A/p16
expression. All 22 paraffin-embedded tumor tissues were
also tested for the expression at protein level of PTGES.
Study blocks were selected after histopathologic review by
a surgical pathologist. The most representative hematox-
ylin- and eosin-stained block sections were used for each
specimen. Sections (4 Am thick) were cut from formalin-
fixed, paraffin-embedded samples, and mounted on charged
slides. Sections were deparaffinized in xylene and rehy-
drated through graded alcohol to distilled water. Antigen
retrieval was performed using Dako Target Retrieval Citrate
Buffer solution (pH 6.0) in a Decloaking Chamber (Biocare
Medical) for 20 min and cooled to room temperature for 30
min following the retrieval process. The slides were then
rinsed in running distilled water and placed in Dako TBS
with Tween (TBST) buffer solution. Endogenous perox-
idase activity was blocked by incubating the slides in Dako
hydrogen peroxidase blocking solution for 10 min. The
slides were rinsed in TBST and incubated for 30 min in
10% normal goat serum (Vector Laboratories) diluted in
TBST to assist in blocking the protein. The slides were
blotted and not rinsed prior to applying the primary
antibody. The slides were incubated for 1 h with a mouse
anti-human p16 antibody (BD Pharmingen) at a 1:75
dilution with Dako antibody diluent with background-
reducing agents or rabbit polyclonal antihuman mPGES
antiserum (Cayman Chemical, Ann Arbor, MI) AT A
1:1000 dilution (2% BSA in PBS) for 18 h at 4 8C. The
slides were rinsed in TBST and the secondary biotinylated
goat anti-mouse antibody or biotinylated anti-rabbit anti-
body was added at a dilution of 1:400 in TBST for 30 min.
The slides were again rinsed in TBST. The avidin–biotin
complex (Vectastain Elite ABC Kit, Vector Laboratories)
was applied and incubated for 30 min. Slides were
developed in DAB + chromogen (DakoCytomation) for 3
min and rinsed in distilled water. Finally, the slides were
counterstained for 2 min in hematoxylin 2 (Richard-Allan
Scientific) and mounted and coverslipped. The intensity of
staining was graded as negative (staining not greater than
A.D. Santin et al. / Virology 331 (2005) 269–291290negative control), 1+ (weak positivity), 2+ (focal intense
positivity), and 3+ (diffuse intense positivity).Acknowledgments
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